account_balance
Investment manager · 13F filer · SEC CIK 1346824
Ra Capital Management, L.P.
Reported value$11.5Bas of Jun 30, 2026
Positions84 17 new, 18 sold out
Top 10 weight60.4%ASND alone is 24%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
ASNDAscendis Pharma A/s
23.8%New
PBLSParabilis Medicines Inc
6.9%New
RYTMRhythm Pharmaceuticals Inc
6.4%
PCVXVaxcyte Inc
5.8%
SIONSionna Therapeutics Inc
3.8%
TYRATyra Biosciences Inc
3.4%
EWTXEdgewise Therapeutics Inc
3.0%Trimmed −20%
NAMSNewamsterdam Pharma Co NV
2.8%
COAGHemab Therapeutics Holdings
2.5%New
SEPN2.0%BCAXBicara Therapeutics Inc
1.9%
MLYSMineralys Therapeutics Inc
1.8%
ASNDAscendis Pharma A/s
23.8%New
PBLS6.9%RYTM6.4%PCVXVaxcyte Inc
5.8%
SION3.8%TYRA3.4%EWTX3.0%NAMS2.8%COAG2.5%SEPNBCAX1.9%MLYS1.8%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
ASND Ascendis Pharma A/s 23.8% NewPBLS Parabilis Medicines Inc 6.9% NewRYTM Rhythm Pharmaceuticals Inc 6.4% HeldPCVX Vaxcyte Inc 5.8% HeldSION Sionna Therapeutics Inc 3.8% HeldTYRA Tyra Biosciences Inc 3.4% HeldEWTX Edgewise Therapeutics Inc 3.0% Trimmed −20%NAMS Newamsterdam Pharma Co NV 2.8% HeldCOAG Hemab Therapeutics Holdings 2.5% NewSEPN Septerna Inc 2.0% HeldBCAX Bicara Therapeutics Inc 1.9% HeldMLYS Mineralys Therapeutics Inc 1.8% Held
What changed